If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

The main focus of our laboratory is developing a better understanding of how key mutations in gliomas alter their biological characteristics, and how best to exploit specific weaknesses that such mutations often impart. In particular, our laboratory focuses on mutant isocitrate dehydrogenase 1 (mutIDH1), which is present in the vast majority of WHO grade II and III gliomas. This mutation has profound effects on the epigenome and metabolome, yet produces tumors that are markedly less aggressive. Our work indicates that mutIDH1 also dramatically alters the glioma’s micro-environmental landscape by preventing the thrombosis-necrosis phenomenon that is characteristic of IDH1 wild-type gliomas. Furthermore, mutIDH1 increases the risk of seizures in patients. We are currently exploring the mechanisms by which these phenomena occur, as it will have major implications for understanding why mutIDH1 gliomas are less aggressive and how to better manage both wtIDH1 and mutIDH1 gliomas. On a clinical level, I specialize in the use of molecular testing in brain tumors to improve our diagnostic and prognostic accuracy. This is helping us achieve the goal of personalized medicine through cutting-edge next generation sequencing.

Training Experience

2004Postdoctoral Fellowship, University of Pittsburgh
2007Residency, University of Pittsburgh
2009Fellowship, University of Pittsburgh

Education/Academic qualification

MD, State University of New York

… → 2003

PhD, State University of New York

… → 2003

Research interests

  • Brain Cancer / Nervous System Cancer
  • Cancer Biology
  • Molecular Diagnostics
  • Pathology

Fingerprint Dive into the research topics where Craig Michael Horbinski is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

  • Research Output

    Advances in multidisciplinary therapy for meningiomas

    International Consortium on Meningiomas, Jan 14 2019, In : Neuro-oncology. 21, p. I18-I31

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations

    Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma (Nature Medicine, (2019), 25, 3, (462-469), 10.1038/s41591-019-0349-y)

    Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz, M., Yamaguchi, J. T., Cloney, M., Horbinski, C., Lukas, R. V., Raizer, J., Rae, A. I., Yuan, J. & 7 others, Canoll, P., Bruce, J. N., Saenger, Y. M., Sims, P., Iwamoto, F. M., Sonabend, A. M. & Rabadan, R., Jun 1 2019, In : Nature Medicine. 25, 6, 1 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • 2 Scopus citations

    Characterization of squamous cell lung cancers from Appalachian Kentucky

    Liu, J., Murali, T., Yu, T., Liu, C., Sivakumaran, T. A., Moseley, H. N. B., Zhulin, I. B., Weiss, H. L., Durbin, E. B., Ellingson, S. R., Liu, J., Huang, B., Hallahan, B. J., Horbinski, C. M., Hodges, K., Napier, D. L., Bocklage, T., Mueller, J., Vanderford, N. L., Fardo, D. W. & 2 others, Wang, C. & Arnold, S. M., Feb 2019, In : Cancer Epidemiology Biomarkers and Prevention. 28, 2, p. 348-356 9 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Clinical Utility of GlioSeq Next-Generation Sequencing Test in Pediatric and Young Adult Patients with Brain Tumors

    Roy, S., Agnihotri, S., El Hallani, S., Ernst, W. L., Wald, A. I., Santana Dos Santos, L., Hamilton, R. L., Horbinski, C. M., Wadhwani, N. R., Born, D. E., Pollack, I. F., Nikiforov, Y. E. & Nikiforova, M. N., Jan 1 2019, In : Journal of neuropathology and experimental neurology. 78, 8, p. 694-702 9 p.

    Research output: Contribution to journalArticle

  • Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

    Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Scholtens, D. M., Savoor, R., Zhang, B., Wu, J. D., Horbinski, C., Lukas, R. V., Binder, D. C. & Wainwright, D. A., Mar 4 2019, In : OncoImmunology. 8, 3, 1548242.

    Research output: Contribution to journalComment/debate